FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015747280> ?p ?o ?g. }

• W2015747280 endingPage "226" @default.
• W2015747280 startingPage "219" @default.
• W2015747280 abstract "Antiepileptic drugs (AEDs)-induced adverse consequences on bone are now well recognized. Despite this, there is limited data on the effect of anti-osteoporotic therapies on AEDs-induced bone loss. We hypothesize that estrogen deprivation following phenytoin (PHT) and sodium valproate (SVP) therapy could lead to adverse bony effects. Both PHT and SVP inhibit human aromatase enzyme and stimulate microsomal catabolism of oestrogens. Estrogen deficiency states are known to reduce the deposition of transforming growth factor-β (TGF-β3), a bone matrix protein, having anti-osteoclastic property. Thus, an attempt was made to investigate the effect of raloxifene, a selective oestrogen receptor modulator, in comparison with calcium and vitamin D3 (CVD) supplementation, on PHT and SVP-induced alterations in bone in mice and to unravel the role of estradiol and TGF-β3 in mediation of bony effects by either AEDs or raloxifene. Further, the effect of raloxifene on seizures and on the antiepileptic efficacy of PHT and SVP was investigated. Swiss strains of female mice were treated with PHT (35 mg/kg, p.o.) and SVP (300 mg/kg, p.o.) for 120 days to induce bone loss as evidenced by reduced bone mineral density (BMD) and altered bone turnover markers (BTMs) in lumbar bones (alkaline phosphatase, tartarate resistant acid phosphatase, hydroxyproline) and urine (calcium). The bone loss was accompanied by reduced serum estradiol levels and bone TGF-β3 content. Preventive and therapeutic treatment with raloxifene ameliorated bony alterations and was more effective than CVD. It also significantly restored estradiol and TGF-β3 levels. Deprived estrogen levels (that in turn reduced lumbar TGF-β3 content) following PHT and SVP, thus, might represent one of the various mechanisms of AEDs-induced bone loss. Raloxifene preserved the bony changes without interfering with antiepileptic efficacy of these drugs, and hence raloxifene could be a potential therapeutic option in the management of PHT and SVP-induced bone disease if clinically approved." @default.
• W2015747280 created "2016-06-24" @default.
• W2015747280 creator A5015342434 @default.
• W2015747280 creator A5019144480 @default.
• W2015747280 creator A5035937945 @default.
• W2015747280 creator A5077609375 @default.
• W2015747280 date "2014-10-01" @default.
• W2015747280 modified "2023-10-01" @default.
• W2015747280 title "Raloxifene preserves phenytoin and sodium valproate induced bone loss by modulating serum estradiol and TGF-β3 content in bone of female mice" @default.
• W2015747280 cites W1533689569 @default.
• W2015747280 cites W1593982346 @default.
• W2015747280 cites W1775749144 @default.
• W2015747280 cites W1964726028 @default.
• W2015747280 cites W1969945802 @default.
• W2015747280 cites W1973207347 @default.
• W2015747280 cites W1974025743 @default.
• W2015747280 cites W1974610909 @default.
• W2015747280 cites W1976236115 @default.
• W2015747280 cites W1979321097 @default.
• W2015747280 cites W1984161137 @default.
• W2015747280 cites W1984210862 @default.
• W2015747280 cites W1987491143 @default.
• W2015747280 cites W1989693389 @default.
• W2015747280 cites W1991462870 @default.
• W2015747280 cites W1992407302 @default.
• W2015747280 cites W1993092485 @default.
• W2015747280 cites W2002975750 @default.
• W2015747280 cites W2003149419 @default.
• W2015747280 cites W2019554446 @default.
• W2015747280 cites W2021729084 @default.
• W2015747280 cites W2022694406 @default.
• W2015747280 cites W2027215054 @default.
• W2015747280 cites W2031329102 @default.
• W2015747280 cites W2032097545 @default.
• W2015747280 cites W2034131055 @default.
• W2015747280 cites W2037551404 @default.
• W2015747280 cites W2047233137 @default.
• W2015747280 cites W2048321750 @default.
• W2015747280 cites W2058766023 @default.
• W2015747280 cites W2058892394 @default.
• W2015747280 cites W2060179744 @default.
• W2015747280 cites W2062884501 @default.
• W2015747280 cites W2065784567 @default.
• W2015747280 cites W2065946490 @default.
• W2015747280 cites W2068185664 @default.
• W2015747280 cites W2072522568 @default.
• W2015747280 cites W2078629043 @default.
• W2015747280 cites W2082200254 @default.
• W2015747280 cites W2112629831 @default.
• W2015747280 cites W2113550509 @default.
• W2015747280 cites W2116130425 @default.
• W2015747280 cites W2132551393 @default.
• W2015747280 cites W2141106453 @default.
• W2015747280 cites W2148624377 @default.
• W2015747280 cites W2155857867 @default.
• W2015747280 cites W2167405461 @default.
• W2015747280 cites W2169649029 @default.
• W2015747280 cites W2171120966 @default.
• W2015747280 cites W2327092610 @default.
• W2015747280 cites W2419619007 @default.
• W2015747280 cites W4232536094 @default.
• W2015747280 doi "https://doi.org/10.1016/j.ejps.2014.05.018" @default.
• W2015747280 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24880111" @default.
• W2015747280 hasPublicationYear "2014" @default.
• W2015747280 type Work @default.
• W2015747280 sameAs 2015747280 @default.
• W2015747280 citedByCount "11" @default.
• W2015747280 countsByYear W20157472802016 @default.
• W2015747280 countsByYear W20157472802017 @default.
• W2015747280 countsByYear W20157472802018 @default.
• W2015747280 countsByYear W20157472802019 @default.
• W2015747280 countsByYear W20157472802021 @default.
• W2015747280 countsByYear W20157472802022 @default.
• W2015747280 countsByYear W20157472802023 @default.
• W2015747280 crossrefType "journal-article" @default.
• W2015747280 hasAuthorship W2015747280A5015342434 @default.
• W2015747280 hasAuthorship W2015747280A5019144480 @default.
• W2015747280 hasAuthorship W2015747280A5035937945 @default.
• W2015747280 hasAuthorship W2015747280A5077609375 @default.
• W2015747280 hasConcept C121608353 @default.
• W2015747280 hasConcept C126322002 @default.
• W2015747280 hasConcept C134018914 @default.
• W2015747280 hasConcept C170033053 @default.
• W2015747280 hasConcept C185592680 @default.
• W2015747280 hasConcept C2776541429 @default.
• W2015747280 hasConcept C2776886416 @default.
• W2015747280 hasConcept C2777164284 @default.
• W2015747280 hasConcept C2777944059 @default.
• W2015747280 hasConcept C2779329777 @default.
• W2015747280 hasConcept C2779889926 @default.
• W2015747280 hasConcept C530470458 @default.
• W2015747280 hasConcept C71924100 @default.
• W2015747280 hasConcept C8264082 @default.
• W2015747280 hasConcept C84606932 @default.
• W2015747280 hasConceptScore W2015747280C121608353 @default.
• W2015747280 hasConceptScore W2015747280C126322002 @default.
• W2015747280 hasConceptScore W2015747280C134018914 @default.
• W2015747280 hasConceptScore W2015747280C170033053 @default.

• next